Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Hematology
Published in: Annals of Hematology 3/2020

Open Access 01-03-2020 | Acute Myeloid Leukemia | Original Article

Identification of CD318 (CDCP1) as novel prognostic marker in AML

Authors: Jonas S. Heitmann, Ilona Hagelstein, Clemens Hinterleitner, Malte Roerden, Gundram Jung, Helmut R. Salih, Melanie Märklin, Joseph Kauer

Published in: Annals of Hematology | Issue 3/2020

Login to get access

Abstract

Genetic and morphological markers are well-established prognostic factors in acute myeloid leukemia (AML). However, further reliable markers are urgently needed to improve risk stratification in AML. CD318 (CDCP1) is a transmembrane protein which in solid tumors promotes formation of metastasis and correlates with poor survival. Despite its broad expression on hematological precursor cells, its prognostic significance in hematological malignancies so far remains unclear. Here, we evaluated the role of CD318 as novel prognostic marker in AML by immunophenotyping of leukemic blasts. Flow cytometric evaluation of CD318 on leukemic cells in 70 AML patients revealed a substantial expression in 40/70 (57%) of all cases. CD318 surface levels were significantly correlated with overall survival in patients receiving anthracycline-based induction therapy or best available alternative therapy. Using receiver-operating characteristics, we established a cut-off value to define CD318lo and CD318hi expression in both cohorts. Notably, high CD318 expression correlated inversely as prognostic marker in both treatment cohorts: as poor prognostic marker in patients receiving intense therapy, whereas upon palliative care it correlated with better outcome. In conclusion, FACS-based determination of CD318 expression may serve as novel prognostic factor depending on implemented therapy in AML patients.
Appendix
Available only for authorised users
Literature
1.
Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Buchner T, Dombret H, Ebert BL, Fenaux P, Larson RA, Levine RL, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz M, Sierra J, Tallman MS, Tien HF, Wei AH, Lowenberg B, Bloomfield CD (2017) Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129(4):424–447. https://​doi.​org/​10.​1182/​blood-2016-08-733196 CrossRefPubMedPubMedCentral
2.
3.
4.
Hooper JD, Zijlstra A, Aimes RT, Liang H, Claassen GF, Tarin D, Testa JE, Quigley JP (2003) Subtractive immunization using highly metastatic human tumor cells identifies SIMA135/CDCP1, a 135 kDa cell surface phosphorylated glycoprotein antigen. Oncogene 22(12):1783CrossRef
5.
Bühring HJ, Kuçi S, Conze T, Rathke G, Bartolović K, Grünebach F, Scherl-Mostageer M, Brümmendorf TH, Schweifer N, Lammers R (2004) CDCP1 identifies a broad spectrum of normal and malignant stem/progenitor cell subsets of hematopoietic and nonhematopoietic origin. Stem Cells 22(3):334–343CrossRef
6.
Conze T, Lammers R, KuÇi S, Scherl-Mostageer M, Schweifer N, Kanz L, Bühring HJ (2003) CDCP1 is a novel marker for hematopoietic stem cells. Ann N Y Acad Sci 996(1):222–226CrossRef
7.
Enyindah-Asonye G, Li Y, Ruth JH, Spassov DS, Hebron KE, Zijlstra A, Moasser MM, Wang B, Singer NG, Cui H (2017) CD318 is a ligand for CD6. Proc Natl Acad Sci 114(33):E6912–E6921CrossRef
8.
Perry SE, Robinson P, Melcher A, Quirke P, Bühring H-J, Cook GP, Blair GE (2007) Expression of the CUB domain containing protein 1 (CDCP1) gene in colorectal tumour cells. FEBS Lett 581(6):1137–1142CrossRef
9.
Ji I, Oda T, Inoue M, Uekita T, Sakai R, Okumura M, Aozasa K, Morii E (2009) Expression of CUB domain containing protein (CDCP1) is correlated with prognosis and survival of patients with adenocarcinoma of lung. Cancer Sci 100(3):429–433CrossRef
10.
Scherl-Mostageer M, Sommergruber W, Abseher R, Hauptmann R, Ambros P, Schweifer N (2001) Identification of a novel gene, CDCP1, overexpressed in human colorectal cancer. Oncogene 20(32):4402–4408CrossRef
11.
Awakura Y, Nakamura E, Takahashi T, Kotani H, Mikami Y, Kadowaki T, Myoumoto A, Akiyama H, Ito N, Kamoto T (2008) Microarray-based identification of CUB-domain containing protein 1 as a potential prognostic marker in conventional renal cell carcinoma. J Cancer Res Clin Oncol 134(12):1363–1369CrossRef
12.
Cao M, Gao J, Zhou H, Huang J, You A, Guo Z, Fang F, Zhang W, Song T, Zhang T (2016) HIF-2α regulates CDCP1 to promote PKCδ-mediated migration in hepatocellular carcinoma. Tumor Biol 37(2):1651–1662CrossRef
13.
Miyazawa Y, Uekita T, Hiraoka N, Fujii S, Kosuge T, Kanai Y, Nojima Y, Sakai R (2010) CUB domain–containing protein 1, a prognostic factor for human pancreatic cancers, promotes cell migration and extracellular matrix degradation. Cancer Res 70(12):5136–5146CrossRef
14.
Alajati A, Guccini I, Pinton S, Garcia-Escudero R, Bernasocchi T, Sarti M, Montani E, Rinaldi A, Montemurro F, Catapano C (2015) Interaction of CDCP1 with HER2 enhances HER2-driven tumorigenesis and promotes trastuzumab resistance in breast cancer. Cell Rep 11(4):564–576CrossRef
15.
Casar B, Rimann I, Kato H, Shattil S, Quigley J, Deryugina E (2014) In vivo cleaved CDCP1 promotes early tumor dissemination via complexing with activated β1 integrin and induction of FAK/PI3K/Akt motility signaling. Oncogene 33(2):255–268CrossRef
16.
Casar B, He Y, Iconomou M, Hooper JD, Quigley JP, Deryugina EI (2012) Blocking of CDCP1 cleavage in vivo prevents Akt-dependent survival and inhibits metastatic colonization through PARP1-mediated apoptosis of cancer cells. Oncogene 31(35):3924–3938CrossRef
17.
Deryugina EI, Conn EM, Wortmann A, Partridge JJ, Kupriyanova TA, Ardi VC, Hooper JD, Quigley JP (2009) Functional role of cell surface CUB domain-containing protein 1 in tumor cell dissemination. Mol Cancer Res 7(8):1197–1211CrossRef
18.
Uekita T, Fujii S, Miyazawa Y, Iwakawa R, Narisawa-Saito M, Nakashima K, Tsuta K, Tsuda H, Kiyono T, Yokota J (2014) Oncogenic Ras/ERK signaling activates CDCP1 to promote tumor invasion and metastasis. Mol Cancer Res 12(10):1449–1459CrossRef
19.
Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C (1985) Proposed revised criteria for the classification of acute myeloid leukemia: a report of the French-American-British Cooperative Group. Ann Intern Med 103(4):620–625CrossRef
20.
Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C (1976) Proposals for the classification of the acute leukaemias French-American-British (FAB) Co-operative Group. Br J Haematol 33(4):451–458CrossRef
21.
O'Donnell MR, Tallman MS, Abboud CN, Altman JK, Appelbaum FR, Arber DA, Bhatt V, Bixby D, Blum W, Coutre SE (2017) Acute myeloid leukemia, version 3.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw 15(7):926–957CrossRef
22.
Dohner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK, Dombret H, Fenaux P, Grimwade D, Larson RA, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz MA, Sierra J, Tallman MS, Lowenberg B, Bloomfield CD, European L (2010) Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 115(3):453–474CrossRef
23.
Ji I, Morii E, Kimura H, Tomita Y, Takakuwa T, Ji H, Kim YK, Miyoshi Y, Noguchi S, Nishida T (2006) Epigenetic regulation of the expression of the novel stem cell marker CDCP1 in cancer cells. J Pathol 210(1):75–84CrossRef
24.
Takeda H, Fujimori Y, Kai S, Ogawa H, Nakano T (2010) CD318/CUB-domain-containing protein 1 expression on cord blood hematopoietic progenitors. Experimental therapeutic Medicine 1(3):497–501CrossRef
25.
Emerling BM, Benes CH, Poulogiannis G, Bell EL, Courtney K, Liu H, Choo-Wing R, Bellinger G, Tsukazawa KS, Brown V (2013) Identification of CDCP1 as a hypoxia-inducible factor 2α (HIF-2α) target gene that is associated with survival in clear cell renal cell carcinoma patients. Proc Natl Acad Sci 110(9):3483–3488CrossRef
26.
Rouault-Pierre K, Lopez-Onieva L, Foster K, Anjos-Afonso F, Lamrissi-Garcia I, Serrano-Sanchez M, Mitter R, Ivanovic Z, de Verneuil H, Gribben J (2013) HIF-2α protects human hematopoietic stem/progenitors and acute myeloid leukemic cells from apoptosis induced by endoplasmic reticulum stress. Cell Stem Cell 13(5):549–563CrossRef
27.
Forristal C, Brown A, Helwani F, Winkler I, Nowlan B, Barbier V, Powell R, Engler G, Diakiw S, Zannettino A (2015) Hypoxia inducible factor (HIF)-2α accelerates disease progression in mouse models of leukemia and lymphoma but is not a poor prognosis factor in human AML. Leukemia 29(10):2075CrossRef
28.
Kollmorgen G, Niederfellner G, Lifke A, Spohn GJ, Rieder N, Vega Harring S, Bauss F, Burtscher H, Lammers R, Bossenmaier B (2013) Antibody mediated CDCP1 degradation as mode of action for cancer targeted therapy. Mol Oncol 7(6):1142–1151CrossRef
29.
Kimura H, Morii E, Ikeda J, Ezoe S, Xu J, Nakamichi N, Tomita Y, Shibayama H, Kanakura Y, Aozasa K (2006) Role of DNA methylation for expression of novel stem cell marker CDCP1 in hematopoietic cells. Leukemia 20(9):1551–1556CrossRef
30.
31.
Covey JM, D'Incalci M, Tilchen EJ, Zaharko DS, Kohn KW (1986) Differences in DNA damage produced by incorporation of 5-aza-2′-deoxycytidine or 5,6-dihydro-5-azacytidine into DNA of mammalian cells. Cancer Res 46(11):5511–5517PubMed
32.
Kollmorgen G, Lifke A, Nopora A, Bauss F, Niederfellner G, Bossenmaier B (2014) RG7287, a novel humanized anti-CDCP1 antibody with superior preclinical in vivo efficacy in combination with paclitaxel. Mol Oncol 7(6):1142–1151CrossRef
Metadata
Title
Identification of CD318 (CDCP1) as novel prognostic marker in AML
Authors
Jonas S. Heitmann
Ilona Hagelstein
Clemens Hinterleitner
Malte Roerden
Gundram Jung
Helmut R. Salih
Melanie Märklin
Joseph Kauer
Publication date
01-03-2020
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology / Issue 3/2020
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-020-03907-9

Other articles of this Issue 3/2020

Annals of Hematology 3/2020 Go to the issue

Original Article

Whole body vibration training during allogeneic hematopoietic cell transplantation—the effects on patients’ physical capacity

Original Article

NFKB1 gene single-nucleotide polymorphisms: implications for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation

Original Article

Impact of clinical features, cytogenetics, genetic mutations, and methylation dynamics of CDKN2B and DLC-1 promoters on treatment response to azacitidine

Letter to the Editor

Trametinib and Dabrafenib in histiocytic sarcoma transdifferentiated from chronic lymphocytic leukemia with a K-RAS and a unique BRAF mutation

Original Article

Impact of marrow blasts percentage on high-grade myelodysplastic syndrome assessed using revised international prognostic scoring system

Letter to the Editor

The Glasgow prognostic score divides high-risk hematopoietic cell transplantation-specific comorbidity index patients into stratified subgroups in allogeneic hematopoietic cell transplantation
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits